Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters
C Xu, A Rafique, T Potocky, A Paccaly… - The Journal of …, 2021 - Wiley Online Library
Abstract We evaluated interleukin‐6 (IL‐6) receptor‐α subunit (IL‐6Rα) signaling inhibition
with sarilumab and tocilizumab, the association between IL‐6Rα receptor occupancy (RO) …
with sarilumab and tocilizumab, the association between IL‐6Rα receptor occupancy (RO) …
[HTML][HTML] Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density …
P Nolain, N Djebli, A Brunet, D Fabre… - European Journal of Drug …, 2022 - Springer
Abstract Background and Objectives Alirocumab is a cholesterol-lowering monoclonal
antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the …
antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the …
Population pharmacokinetics of levobupivacaine during transversus abdominis plane block in children
M Vincent, O Mathieu, P Nolain… - Therapeutic Drug …, 2020 - journals.lww.com
Background: Levobupivacaine is commonly used during transversus abdominis plane (TAP)
block in pediatric patients. However, the dosing regimen is still empirical, and the …
block in pediatric patients. However, the dosing regimen is still empirical, and the …
FRI0106 Sarilumab and tocilizumab receptor occupancy (RO), and effects on C-reactive protein (CRP) levels, in patients with rheumatoid arthritis (RA)
C Xu, P Nolain, Q Lu, A Paccaly, M Iglesias-Rodriguez… - 2019 - ard.bmj.com
Background Objectives The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human
interleukin-6 receptor (IL-6R) is 15-to 22-fold higher than tocilizumab. 1 We explored the …
interleukin-6 receptor (IL-6R) is 15-to 22-fold higher than tocilizumab. 1 We explored the …
[CITATION][C] Développement d'un modèle pharmacocinétique/pharmacodynamique semi-mécanistique de l'alirocumab et de son effet hypolipémiant
P Nolain - 2019